<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01637272</url>
  </required_header>
  <id_info>
    <org_study_id>CSOM230X2203</org_study_id>
    <secondary_id>2012-001534-34</secondary_id>
    <nct_id>NCT01637272</nct_id>
  </id_info>
  <brief_title>Phase II Study Evaluating Efficacy, Safety and Pharmacokinetics of Pasireotide in Patients With Dumping Syndrome</brief_title>
  <official_title>A Multi-center, Intra-patient Dose Escalation Phase II Study to Evaluate the Preliminary Efficacy, Safety and Pharmacokinetics of Pasireotide (SOM230) Subcutaneous (s.c.) Followed by Pasireotide LAR in Patients With Dumping Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      multi-center, phase II study evaluating efficacy, safety and pharmacokinetics of pasireotide
      in patients with dumping syndrome
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      43 adult patients with dumping syndrome received pasireotide s.c. during the dose escalation
      phase (3 months dose could be increased based on the presence of hypoglycemia during OGTT).
      After completing Month 3, patients were switched to pasireotide LAR for 3 months (up to Month
      6). The core phase of the study was completed at the end of Month 6. Patients were allowed to
      enter the 6 month extension phase if they experienced benefit with pasireotide LAR treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 8, 2013</start_date>
  <completion_date type="Actual">August 7, 2015</completion_date>
  <primary_completion_date type="Actual">August 7, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate in Plasma Glucose Level</measure>
    <time_frame>at Month 3 (M3)</time_frame>
    <description>Response rate is defined as percentage of patients with no glucose values &lt; 60 mg/dL at 90,120, 150 and 180 min during the Oral Glucose Tolerance Test (OGTT) at the end of s.c. dose escalation phase</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate in Plasma Glucose Level</measure>
    <time_frame>at Month 6 (M6), Month 12 (M12)</time_frame>
    <description>Response rate is defined as percentage of patients with no glucose values &lt; 60 mg/dL at 90,120, 150 and 180 min during the Oral Glucose Tolerance Test (OGTT) at the end of 6 months (end of LAR/Core phase) and at the end of 12 months (extension phase)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate in Pulse Rate</measure>
    <time_frame>at baseline, M3, M6, M12</time_frame>
    <description>Pulse rate was defined as percentage of patients with change in pulse rate &gt;=10 bpm from pre-OGTT to 30 minutes post OGTT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>﻿Response Rate in Hematocrit Levels</measure>
    <time_frame>M3, M6, M12</time_frame>
    <description>﻿Percentage of patients with change in hematocrit &gt;= 3% from pre-OGTT to 30 minutes post OGTT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>﻿Insulin Levels During OGTT</measure>
    <time_frame>M3, M6, M12</time_frame>
    <description>Absolute insulin levels at the end of M3, M6, M12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>﻿Glucagon Levels During OGTT</measure>
    <time_frame>M3, M6, M12</time_frame>
    <description>Absolute glucagon levels at the end of Months 3, 6 &amp; 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>﻿﻿Glucagon-like Peptide 1 (GLP-1) Levels During OGTT</measure>
    <time_frame>M3, M6, M12</time_frame>
    <description>Absolute ﻿Glucagon-like peptide 1 (GLP-1) levels at the end of at the end of Months 3, 6 and 12 at different time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>﻿﻿Gastric Inhibitory Polypeptide (GIP) Levels at During OGTT</measure>
    <time_frame>M3, M6, M12</time_frame>
    <description>Absolute ﻿﻿﻿Gastric Inhibitory Polypeptide (GIP) levels at the end of Months 3, 6 and 12 at different time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>﻿Health-related Quality of Live (HRQoL) Short Form- 36 (SF-36) Score(s)</measure>
    <time_frame>M3, M6, M12</time_frame>
    <description>Absolute HRQoL SF-36 Scores at end of the Months 3, 6 and 12 from s.c. baseline. SF-36, a 36-Item Short Form Health Survey (SF-36) is a set of generic, coherent, and easily administered quality-of-life measures. These measures rely upon patient self-reporting. Items are scored so that a high score defines a more favorable health state. In addition, each item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>﻿Dumping Severity Score (DSS) at the End of Months 3, 6 and 8</measure>
    <time_frame>M3, M6, M8</time_frame>
    <description>Absolute Dumping Severity Score (DSS) scores at end of M3, M6 &amp; M8. At study start patients were assessed using DSS (older version of DSQ); however after the implementation of protocol amendment 2, all patients were expected to use DSQ. No results available for M12 as last patient that answered the DSS was at M8. DSS = disease-specific patient (Pt.) reported outcome (PRO) questionnaire uses a 4-point Likert scale (0, absent; 1, mild; 2, relevant; 3, severe; 4) to ask Pt. to evaluate intensity of early dumping symptoms (within 30 minutes (&lt;30 minutes) after food ingestion). The questionnaire also evaluates 65 late dumping symptoms (more than 1.5 hours (&gt;90 minutes) after food ingestion). Early &amp; late dumping score calculated by adding the scores of the respective questions. Cumulative dumping score is obtained by adding early &amp; late scores. DSS Range (min (absent) - max (severe)): Early dumping: 0-24; Late Dumping: 0-18; Cumulative: 0-42. Lower scores represent a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>﻿Dumping Score Questionnaire (DSQ) at the End of Months 3, 6 and 12</measure>
    <time_frame>M3, M6, M12</time_frame>
    <description>Absolute Dumping Score Questionnaire (DSQ) scores at end of Months 3, 6 &amp; 12 from s.c. baseline. DSQ = disease-specific PRO scale. The questionnaire uses a 5-point Likert scale (0, none; 1, mild; 2, moderate; 3, severe; 4, very severe) to ask Pt. to evaluate intensity of 10 early dumping symptoms (within 30 minutes (&lt;30 minutes) after food ingestion). The questionnaire also evaluates 5 late dumping symptoms (more than 1.5 hours (&gt;90 minutes) after food ingestion). Early &amp; late dumping score calculated by adding the scores of respective questions. A cumulative dumping score is obtained by adding early &amp; late scores. At study start patients were assessed using DSS (older version of DSQ); however after the implementation of protocol amendment 2, all patients used DSQ. DSQ Range: (min (None) - max (Very severe)): Early dumping: 0-40; Late Dumping: 0-20; Cumulative: 0-60. Lower scores represent a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Assessment at the End of Months 3, 6 and 12</measure>
    <time_frame>M3, M6, M12</time_frame>
    <description>Treatment with pasireotide LAR (both early and late dumping scores), was assessed by patient global assessment. Patient Global Assessment served as an additional approach to symptom based measurement by DSQ. It incorporated a patient global assessment question: &quot;Considering all the ways that your disease affects you, rate how you are feeling during the last 7 days compared with your situation before starting the study&quot; .Patients Global Assessment was measured utilizing a 7 point scale (from 1=a lot worse to 7= a lot better).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetic (PK) Parameter of Pasireotide: Cmax, ss (Steady State) and Ctrough, ss, After s.c. Injection</measure>
    <time_frame>M1 to M3</time_frame>
    <description>A pre-dose PK blood sample was collected before the morning pasireotide s.c. dose of 50 μg, 100 ug, 150 ug and 200 ug. OGTT was performed right after the morning s.c. dose (Time point zero); additional PK blood samples were collected at the same time points as the OGTT evaluation at 30, 60, 90, 120, 150 and 180 minutes. 'n' = number of subjects with non-missing values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetic (PK) Parameter of Pasireotide: AUC0-3h, ss, After s.c. Injection</measure>
    <time_frame>M1 to M3</time_frame>
    <description>A pre-dose PK blood sample was collected before the morning pasireotide s.c. dose of 50 μg, 100 ug, 150 ug and 200 ug. OGTT was performed right after the morning s.c. dose (Time point zero); additional PK blood samples were collected at the same time points as the OGTT evaluation at 30, 60, 90, 120, 150 and 180 minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetic (PK) Parameter of Pasireotide: Tmax, ss, After s.c. Injection</measure>
    <time_frame>M1 to M3</time_frame>
    <description>A pre-dose PK blood sample was collected before the morning pasireotide s.c. dose of 50 μg, 100 ug, 150 ug and 200 ug. OGTT was performed right after the morning s.c. dose (Time point zero); additional PK blood samples were collected at the same time points as the OGTT evaluation at 30, 60, 90, 120, 150 and 180 minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK Parameter of AUC0-3h, d21, End _inj and AUC0-3h, d28, 3rd_inj Associated With LAR (LAR Core Phase)</measure>
    <time_frame>M4 to M6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of LAR PK Parameters by Dose</measure>
    <time_frame>M4 to M6</time_frame>
    <description>Summary of plasma PK parameter Cmax, p2 , 2nd injection and Ctrough, d28 associated with LAR injection (LAR Core phase)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pasireotide Concentrations in LAR Phase</measure>
    <time_frame>M7 to M12</time_frame>
    <description>Summary of pasireotide concentrations following monthly i.m. injections of pasireotide LAR by incident dose (LAR Pharmacokinetic set)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LAR PK Parameter: Ctrough - at Steady State (ss) by Dose</measure>
    <time_frame>M4 to M12</time_frame>
    <description>In the LAR treatment phase, monthly injections of pasireotide LAR 10, 20, 30 and 40 mg were given to participants and trough concentration at steady state (Ctrough,ss) were obtained but due to only 1 participant in the 40mg arm, standard deviation could not be calculated.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Dumping Syndrome</condition>
  <arm_group>
    <arm_group_label>SOM230</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with dumping syndrome treated with pasireotide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOM230</intervention_name>
    <description>Pasireotide (SOM230) sc injection was provided as solution for injection in individual 1-point-cut 1 mL ampule, containing nominally 200 μg of pasireotide (as free base). Doses: 50, 100, 150 and 200 μg. Pasireotide im LAR depot injection was provided as micro particles powder in vials containing nominally 10, 20, 40 &amp; 60 mg of pasireotide (as free base) &amp; solvent for suspension for injection in ampules for the reconstitution of the LAR micro particles. Doses: 10, 20, 30, 40 or 60 mg</description>
    <arm_group_label>SOM230</arm_group_label>
    <other_name>pasireotide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:.

          -  Male or female patients ≥ 18 years of age.

          -  Post-gastric or esophageal bypass surgery, matching one of the criteria below:

          -  Bariatric surgery: more than 6 months before signing the informed consent

          -  Esophageal cancer surgery: were disease free at study entry

          -  Gastric cancer surgery: were at stage 0 or I and were disease free at study entry

          -  Patient with a documented diagnosis of Dumping Syndrome defined as having:

          -  History of/or active symptoms associated with dumping syndrome (e.g. post-prandial
             tachycardia, bloating, diarrhea) and

          -  Documented history of hypoglycemia based on either:

          -  glucose &lt;50 mg/dL or 2.8 mmol/L on a sporadic or scheduled blood analysis -or

          -  glucose value &lt;60 mg/dL or ≤ 3.3 mmol/L at 90, 120, 150 or 180 min during an OGTT

          -  Patients had at least one glucose level &lt;60 mg/dL (or ≤ 3.3 mmol/L) at 90, 120, 150 or
             180 min during the 3-hour OGTT at screening.

          -  Patients with esophageal cancer with a negative computed tomography (CT) or Magnetic
             resonance imaging (MRI) scan (neck, thoracic, and upper abdominal) and albumin

             ≥ 3.5 g/dl at baseline.

          -  Patients with gastric cancer with a negative CT or MRI scan (total abdomen).

          -  Karnofsky Performance Status ≥ 60 (i.e. required occasional assistance, but was able
             to care for most of their personal needs)

          -  Patients who received other therapies for dumping syndrome (such as acarbose, gama
             guar, pectin) must have stopped all treatments and had a wash out period prior to
             signing the informed consent (i.e. at least 2 weeks between last previous therapy and
             first dose of study medication in this study).

          -  Patients who had provided signed written informed consent prior to study
             participation.

        Exclusion Criteria:

          -  Bariatric patients who had lap band.

          -  Patients with a current diagnosis of diabetes mellitus.

          -  Patients who had failed treatment with somatostatin analogues for dumping syndrome in
             the past.

          -  Patients who had been treated with somatostatin analogues in the past, must have had
             an appropriate interval between the last administration of somatostatin analogues
             treatment and the study drug as follows

          -  Octreotide sc for ≥ 72 hours

          -  Octreotide LAR for ≥ 56 days (8 weeks)

          -  Lanreotide Autogel for ≥ 98 days (14 weeks)

          -  Lanreotide SR ≥ 28 days (4 weeks)

          -  Patients who were already treated with pasireotide.

          -  Patients who had a known hypersensitivity to somatostatin analogues.

          -  Patients who were receiving anti-cancer therapy (chemotherapy and/or radiotherapy).

          -  Patients who had any severe and/or uncontrolled medical conditions or other conditions
             that could affect their participation in the study such as:

          -  Patients with the presence of active or suspected acute or chronic uncontrolled
             infection or with a history of immunodeficiency, including a positive human
             immunodeficiency virus (HIV) test result (ELISA and Western blot). An HIV test was not
             required; however, previous medical history was reviewed.

          -  Non-malignant medical illnesses that were uncontrolled or whose control may have been
             jeopardized by the treatment with this study treatment.

          -  Life-threatening autoimmune and ischemic disorders.

          -  Patients with the presence of active or suspected acute or chronic uncontrolled
             infection.

        Inadequate end organ function as defined by:

          -  Inadequate bone marrow function:

          -  White blood cells (WBC) &lt;2.5 x 109/L

          -  Absolute neutrophil count &lt;1.5 x 109/L

          -  Platelets &lt;100 x 109/L

          -  Hemoglobin &lt;9 g/dL

          -  International normalized ratio (INR) ≥ 1.3

          -  Serum creatinine &gt;2.0 mg/dL

          -  Alkaline phosphatase (ALP) &gt;2.5 x upper limit of normal (ULN)

          -  Serum total bilirubin &gt;1.5 x ULN

          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) &gt;2 x ULN

          -  History of liver disease, such as cirrhosis or chronic active hepatitis B and C.

          -  Presence of Hepatitis B surface antigen (HbsAg) and/ or presence of Hepatitis C
             antibody test (anti-Hepatitis C Virus).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ximed Center for Weight Management Ximed Research</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center SC - SOM230X2203</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Rochester Mayo MN</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center CLCZ696B2320</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Tech University Health Science Center</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Endocrinology Research SC</name>
      <address>
        <city>Chesapeake</city>
        <state>Virginia</state>
        <zip>23321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brugge</city>
        <zip>8310</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris Cedex 13</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pessac Cedex</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pierre-Benite Cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Utrecht</city>
        <zip>3584CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2012</study_first_submitted>
  <study_first_submitted_qc>July 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2012</study_first_posted>
  <results_first_submitted>July 29, 2016</results_first_submitted>
  <results_first_submitted_qc>March 31, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 10, 2017</results_first_posted>
  <last_update_submitted>March 31, 2017</last_update_submitted>
  <last_update_submitted_qc>March 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dumping syndrome</keyword>
  <keyword>SOM230</keyword>
  <keyword>pasireotide LAR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Dumping Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pasireotide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>43 patients were enrolled as planned; 33 patients completed the core sc phase, 31 patients completed the core LAR phase. Of the 31 patients who completed core LAR phase, 27 patients entered the extension phase. Of the 27 patients who entered the extension phase, 23 patients completed the study.</recruitment_details>
      <pre_assignment_details>All patients underwent an OGTT (75g of glucose) and were evaluated at different time points. If the glucose level was &lt;60 mg/dL at 90, 120, 150 or 180 min during the OGTT and all the other eligibility criteria were met, patients were allowed to start study medication. The study was divided in 2 phases, core phase and extension phase.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>SOM230</title>
          <description>Subjects with dumping syndrome treated with pasireotide</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed sc Phase</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Core Phase (sc + LAR)</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Entered Extension Phase</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Core But Did no Enter Ext..</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory therapeutic effect</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>completed core, did not enter ext. phase</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The overall study full analysis set (FAS) consisted of all patients who were enrolled in the study (whether treated or not).</population>
      <group_list>
        <group group_id="B1">
          <title>SOM230</title>
          <description>Subjects with dumping syndrome treated with pasireotide</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.9" spread="9.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate in Plasma Glucose Level</title>
        <description>Response rate is defined as percentage of patients with no glucose values &lt; 60 mg/dL at 90,120, 150 and 180 min during the Oral Glucose Tolerance Test (OGTT) at the end of s.c. dose escalation phase</description>
        <time_frame>at Month 3 (M3)</time_frame>
        <population>The sc full analysis set (sc FAS) consisted of all patients who received at least one dose of pasireotide sc during core sc phase.</population>
        <group_list>
          <group group_id="O1">
            <title>SOM230 - 3 Months (sc)</title>
            <description>Subjects with dumping syndrome treated with pasireotide sc</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate in Plasma Glucose Level</title>
          <description>Response rate is defined as percentage of patients with no glucose values &lt; 60 mg/dL at 90,120, 150 and 180 min during the Oral Glucose Tolerance Test (OGTT) at the end of s.c. dose escalation phase</description>
          <population>The sc full analysis set (sc FAS) consisted of all patients who received at least one dose of pasireotide sc during core sc phase.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.5" lower_limit="44.41" upper_limit="75.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate in Plasma Glucose Level</title>
        <description>Response rate is defined as percentage of patients with no glucose values &lt; 60 mg/dL at 90,120, 150 and 180 min during the Oral Glucose Tolerance Test (OGTT) at the end of 6 months (end of LAR/Core phase) and at the end of 12 months (extension phase)</description>
        <time_frame>at Month 6 (M6), Month 12 (M12)</time_frame>
        <population>The LAR full analysis set (LAR FAS) consisted of all patients who received at least one dose of pasireotide LAR during core LAR phase.</population>
        <group_list>
          <group group_id="O1">
            <title>SOM230- 6 Months (LAR)</title>
            <description>Subjects with dumping syndrome treated with pasireotide sc (3M)followed by pasireotide LAR (3M) for a total of 6 months</description>
          </group>
          <group group_id="O2">
            <title>SOM230 - 12 Months (Ext)</title>
            <description>Subjects with dumping syndrome treated with pasireotide LAR (6 months in Core &amp; 6 months in Ext. phase)</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate in Plasma Glucose Level</title>
          <description>Response rate is defined as percentage of patients with no glucose values &lt; 60 mg/dL at 90,120, 150 and 180 min during the Oral Glucose Tolerance Test (OGTT) at the end of 6 months (end of LAR/Core phase) and at the end of 12 months (extension phase)</description>
          <population>The LAR full analysis set (LAR FAS) consisted of all patients who received at least one dose of pasireotide LAR during core LAR phase.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4" lower_limit="20.40" upper_limit="54.88"/>
                    <measurement group_id="O2" value="39.4" lower_limit="22.91" upper_limit="57.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate in Pulse Rate</title>
        <description>Pulse rate was defined as percentage of patients with change in pulse rate &gt;=10 bpm from pre-OGTT to 30 minutes post OGTT.</description>
        <time_frame>at baseline, M3, M6, M12</time_frame>
        <population>The sc full analysis set (sc FAS) consisted of all patients who received at least one dose of pasireotide sc during core sc phase. The LAR full analysis set (LAR FAS) consisted of all patients who received at least one dose of pasireotide LAR during core LAR phase.</population>
        <group_list>
          <group group_id="O1">
            <title>SOM230 - 3 Months (sc)</title>
            <description>Subjects with dumping syndrome treated with pasireotide sc</description>
          </group>
          <group group_id="O2">
            <title>SOM230 - 6 Months (LAR)</title>
            <description>Subjects with dumping syndrome treated with pasireotide sc (3M) followed by pasireotide LAR (3M) for a total of 6 months</description>
          </group>
          <group group_id="O3">
            <title>SOM230 - 12 Months (Ext)</title>
            <description>Subjects with dumping syndrome treated with pasireotide LAR (6 months in Core &amp; 6 months in Ext. phase)</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate in Pulse Rate</title>
          <description>Pulse rate was defined as percentage of patients with change in pulse rate &gt;=10 bpm from pre-OGTT to 30 minutes post OGTT.</description>
          <population>The sc full analysis set (sc FAS) consisted of all patients who received at least one dose of pasireotide sc during core sc phase. The LAR full analysis set (LAR FAS) consisted of all patients who received at least one dose of pasireotide LAR during core LAR phase.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>rate ≥ 10 bpm at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.5"/>
                    <measurement group_id="O2" value="24.2"/>
                    <measurement group_id="O3" value="24.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rate ≥ 10 bpm at post-baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6"/>
                    <measurement group_id="O2" value="36.4"/>
                    <measurement group_id="O3" value="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>﻿Response Rate in Hematocrit Levels</title>
        <description>﻿Percentage of patients with change in hematocrit &gt;= 3% from pre-OGTT to 30 minutes post OGTT.</description>
        <time_frame>M3, M6, M12</time_frame>
        <population>The sc full analysis set (sc FAS) consisted of all patients who received at least one dose of pasireotide sc during core sc phase. The LAR full analysis set (LAR FAS) consisted of all patients who received at least one dose of pasireotide LAR during core LAR phase.</population>
        <group_list>
          <group group_id="O1">
            <title>SOM230 - 3 Months (sc)</title>
            <description>Subjects with dumping syndrome treated with pasireotide sc</description>
          </group>
          <group group_id="O2">
            <title>SOM230 - 6 Months (LAR)</title>
            <description>Subjects with dumping syndrome treated with pasireotide sc (3M) followed by pasireotide LAR (3M) for a total of 6 months</description>
          </group>
          <group group_id="O3">
            <title>SOM230 - 12 Months (Ext)</title>
            <description>Subjects with dumping syndrome treated with pasireotide LAR (6 months in Core &amp; 6 months in Ext. phase)</description>
          </group>
        </group_list>
        <measure>
          <title>﻿Response Rate in Hematocrit Levels</title>
          <description>﻿Percentage of patients with change in hematocrit &gt;= 3% from pre-OGTT to 30 minutes post OGTT.</description>
          <population>The sc full analysis set (sc FAS) consisted of all patients who received at least one dose of pasireotide sc during core sc phase. The LAR full analysis set (LAR FAS) consisted of all patients who received at least one dose of pasireotide LAR during core LAR phase.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>hematocrit &gt;= 3% at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.9"/>
                    <measurement group_id="O2" value="21.2"/>
                    <measurement group_id="O3" value="21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hematocrit &gt;= 3% at post baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3"/>
                    <measurement group_id="O2" value="27.3"/>
                    <measurement group_id="O3" value="24.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>﻿Insulin Levels During OGTT</title>
        <description>Absolute insulin levels at the end of M3, M6, M12</description>
        <time_frame>M3, M6, M12</time_frame>
        <population>The sc full analysis set (sc FAS) consisted of all patients who received at least one dose of pasireotide sc during core sc phase. The LAR full analysis set (LAR FAS) consisted of all patients who received at least one dose of pasireotide LAR during core LAR phase.</population>
        <group_list>
          <group group_id="O1">
            <title>SOM230 - 3 Months (sc)</title>
            <description>Subjects with dumping syndrome treated with pasireotide sc</description>
          </group>
          <group group_id="O2">
            <title>SOM230 - 6 Months (LAR)</title>
            <description>Subjects with dumping syndrome treated with pasireotide sc (3M) followed by pasireotide LAR (3M) for a total of 6 months</description>
          </group>
          <group group_id="O3">
            <title>SOM230 - 12 Months (Ext)</title>
            <description>Subjects with dumping syndrome treated with pasireotide LAR (6 months in Core &amp; 6 months in Ext. phase)</description>
          </group>
        </group_list>
        <measure>
          <title>﻿Insulin Levels During OGTT</title>
          <description>Absolute insulin levels at the end of M3, M6, M12</description>
          <population>The sc full analysis set (sc FAS) consisted of all patients who received at least one dose of pasireotide sc during core sc phase. The LAR full analysis set (LAR FAS) consisted of all patients who received at least one dose of pasireotide LAR during core LAR phase.</population>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-OGTT (n= 31, 29, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.0" spread="24.55"/>
                    <measurement group_id="O2" value="34.7" spread="19.73"/>
                    <measurement group_id="O3" value="29.0" spread="14.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Minutes (n=30, 29, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196.3" spread="253.10"/>
                    <measurement group_id="O2" value="499.8" spread="276.80"/>
                    <measurement group_id="O3" value="294.1" spread="177.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 Minutes (n= 31, 30, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="367.5" spread="354.73"/>
                    <measurement group_id="O2" value="573.2" spread="428.46"/>
                    <measurement group_id="O3" value="602.1" spread="381.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90 Minutes (n=31, 30, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="309.1" spread="263.92"/>
                    <measurement group_id="O2" value="420.4" spread="544.78"/>
                    <measurement group_id="O3" value="472.0" spread="438.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 Minutes(n=32, 30, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183.7" spread="209.90"/>
                    <measurement group_id="O2" value="205.7" spread="514.45"/>
                    <measurement group_id="O3" value="195.1" spread="247.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>150 Minutes(n=33, 30, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.2" spread="166.67"/>
                    <measurement group_id="O2" value="102.8" spread="228.92"/>
                    <measurement group_id="O3" value="76.0" spread="106.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>180 Minutes (n=32, 29, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.5" spread="52.65"/>
                    <measurement group_id="O2" value="69.1" spread="154.11"/>
                    <measurement group_id="O3" value="52.0" spread="58.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>﻿Glucagon Levels During OGTT</title>
        <description>Absolute glucagon levels at the end of Months 3, 6 &amp; 12</description>
        <time_frame>M3, M6, M12</time_frame>
        <population>The sc full analysis set (sc FAS) consisted of all patients who received at least one dose of pasireotide sc during core sc phase. The LAR full analysis set (LAR FAS) consisted of all patients who received at least one dose of pasireotide LAR during core LAR phase.</population>
        <group_list>
          <group group_id="O1">
            <title>SOM230 - 3 Months (sc)</title>
            <description>Subjects with dumping syndrome treated with pasireotide sc</description>
          </group>
          <group group_id="O2">
            <title>SOM230 - 6 Months (LAR)</title>
            <description>Subjects with dumping syndrome treated with pasireotide sc (3M) followed by pasireotide LAR (3M) for a total of 6 months</description>
          </group>
          <group group_id="O3">
            <title>SOM230 - 12 Months (Ext)</title>
            <description>Subjects with dumping syndrome treated with pasireotide LAR (6 months in Core &amp; 6 months in Ext. phase)</description>
          </group>
        </group_list>
        <measure>
          <title>﻿Glucagon Levels During OGTT</title>
          <description>Absolute glucagon levels at the end of Months 3, 6 &amp; 12</description>
          <population>The sc full analysis set (sc FAS) consisted of all patients who received at least one dose of pasireotide sc during core sc phase. The LAR full analysis set (LAR FAS) consisted of all patients who received at least one dose of pasireotide LAR during core LAR phase.</population>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-OGTT (n= 31, 30, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.70" spread="6.162"/>
                    <measurement group_id="O2" value="22.6" spread="5.85"/>
                    <measurement group_id="O3" value="21.4" spread="6.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Minutes (n= 33, 29, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.64" spread="7.037"/>
                    <measurement group_id="O2" value="25.8" spread="6.57"/>
                    <measurement group_id="O3" value="23.8" spread="6.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 Minutes (n= 33, 28, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.80" spread="7.330"/>
                    <measurement group_id="O2" value="23.7" spread="5.76"/>
                    <measurement group_id="O3" value="22.9" spread="7.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90 Minutes (n= 32, 29, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.07" spread="7.898"/>
                    <measurement group_id="O2" value="22.7" spread="5.16"/>
                    <measurement group_id="O3" value="21.5" spread="7.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 Minutes (n= 32, 29, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.73" spread="7.369"/>
                    <measurement group_id="O2" value="23.1" spread="5.40"/>
                    <measurement group_id="O3" value="22.0" spread="7.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>150 Minutes (n= 32 28, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.94" spread="7.169"/>
                    <measurement group_id="O2" value="23.7" spread="6.67"/>
                    <measurement group_id="O3" value="21.8" spread="7.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>180 Minutes (n= 32, 29, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.16" spread="7.097"/>
                    <measurement group_id="O2" value="22.7" spread="5.45"/>
                    <measurement group_id="O3" value="22.3" spread="6.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>﻿﻿Glucagon-like Peptide 1 (GLP-1) Levels During OGTT</title>
        <description>Absolute ﻿Glucagon-like peptide 1 (GLP-1) levels at the end of at the end of Months 3, 6 and 12 at different time points.</description>
        <time_frame>M3, M6, M12</time_frame>
        <population>The sc full analysis set (sc FAS) consisted of all patients who received at least one dose of pasireotide sc during core sc phase. The LAR full analysis set (LAR FAS) consisted of all patients who received at least one dose of pasireotide LAR during core LAR phase.</population>
        <group_list>
          <group group_id="O1">
            <title>SOM230 - 3 Months (sc)</title>
            <description>Subjects with dumping syndrome treated with pasireotide sc</description>
          </group>
          <group group_id="O2">
            <title>SOM230 - 6 Months (LAR)</title>
            <description>Subjects with dumping syndrome treated with pasireotide sc (3M) followed by pasireotide LAR (3M) for a total of 6 months</description>
          </group>
          <group group_id="O3">
            <title>SOM230 - 12 Months (Ext)</title>
            <description>Subjects with dumping syndrome treated with pasireotide LAR (6 months in Core &amp; 6 months in Ext. phase)</description>
          </group>
        </group_list>
        <measure>
          <title>﻿﻿Glucagon-like Peptide 1 (GLP-1) Levels During OGTT</title>
          <description>Absolute ﻿Glucagon-like peptide 1 (GLP-1) levels at the end of at the end of Months 3, 6 and 12 at different time points.</description>
          <population>The sc full analysis set (sc FAS) consisted of all patients who received at least one dose of pasireotide sc during core sc phase. The LAR full analysis set (LAR FAS) consisted of all patients who received at least one dose of pasireotide LAR during core LAR phase.</population>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-OGTT (n=31, 29, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.021" spread="2.1936"/>
                    <measurement group_id="O2" value="2.1" spread="1.37"/>
                    <measurement group_id="O3" value="1.6" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Minutes(n=32, 29, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.811" spread="6.6194"/>
                    <measurement group_id="O2" value="21.0" spread="18.01"/>
                    <measurement group_id="O3" value="17.4" spread="17.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 Minutes (n= 32, 30, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.208" spread="11.1218"/>
                    <measurement group_id="O2" value="14.6" spread="18.44"/>
                    <measurement group_id="O3" value="12.6" spread="8.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90 Minutes (n=31, 29, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.986" spread="4.9729"/>
                    <measurement group_id="O2" value="8.2" spread="4.96"/>
                    <measurement group_id="O3" value="7.2" spread="3.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 Minutes (n=31, 29, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.003" spread="4.1183"/>
                    <measurement group_id="O2" value="5.2" spread="3.94"/>
                    <measurement group_id="O3" value="5.0" spread="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>150 Minutes(n=31, 29, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.565" spread="2.3879"/>
                    <measurement group_id="O2" value="4.2" spread="4.20"/>
                    <measurement group_id="O3" value="3.7" spread="2.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>180 Minutes (n=31, 29, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.974" spread="1.9902"/>
                    <measurement group_id="O2" value="3.3" spread="3.49"/>
                    <measurement group_id="O3" value="3.2" spread="2.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>﻿﻿Gastric Inhibitory Polypeptide (GIP) Levels at During OGTT</title>
        <description>Absolute ﻿﻿﻿Gastric Inhibitory Polypeptide (GIP) levels at the end of Months 3, 6 and 12 at different time points.</description>
        <time_frame>M3, M6, M12</time_frame>
        <population>The sc full analysis set (sc FAS) consisted of all patients who received at least one dose of pasireotide sc during core sc phase.
The LAR full analysis set (LAR FAS) consisted of all patients who received at least one dose of pasireotide LAR during core LAR phase.</population>
        <group_list>
          <group group_id="O1">
            <title>SOM230 - 3 Months (sc)</title>
            <description>Subjects with dumping syndrome treated with pasireotide sc</description>
          </group>
          <group group_id="O2">
            <title>SOM230 - 6 Months (LAR)</title>
            <description>Subjects with dumping syndrome treated with pasireotide sc (3M) followed by pasireotide LAR (3M) for a total of 6 months</description>
          </group>
          <group group_id="O3">
            <title>SOM230 - 12 Months (Ext)</title>
            <description>Subjects with dumping syndrome treated with pasireotide LAR (6 months in Core &amp; 6 months in Ext. phase)</description>
          </group>
        </group_list>
        <measure>
          <title>﻿﻿Gastric Inhibitory Polypeptide (GIP) Levels at During OGTT</title>
          <description>Absolute ﻿﻿﻿Gastric Inhibitory Polypeptide (GIP) levels at the end of Months 3, 6 and 12 at different time points.</description>
          <population>The sc full analysis set (sc FAS) consisted of all patients who received at least one dose of pasireotide sc during core sc phase.
The LAR full analysis set (LAR FAS) consisted of all patients who received at least one dose of pasireotide LAR during core LAR phase.</population>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-OGTT (n=31, 29, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.608" spread="1.7441"/>
                    <measurement group_id="O2" value="1.5" spread="1.00"/>
                    <measurement group_id="O3" value="1.7" spread="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Minutes (n=32, 29, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.704" spread="10.6395"/>
                    <measurement group_id="O2" value="30.3" spread="19.73"/>
                    <measurement group_id="O3" value="24.8" spread="18.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 Minutes (n= 32, 30, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.471" spread="6.1861"/>
                    <measurement group_id="O2" value="14.3" spread="13.37"/>
                    <measurement group_id="O3" value="11.6" spread="9.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90 Minutes(n=31, 29, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.141" spread="2.8978"/>
                    <measurement group_id="O2" value="6.5" spread="7.32"/>
                    <measurement group_id="O3" value="5.2" spread="5.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 Minutes (n=31, 29, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.089" spread="1.4681"/>
                    <measurement group_id="O2" value="2.4" spread="1.73"/>
                    <measurement group_id="O3" value="3.0" spread="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>150 Minutes (n=30, 29, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.376" spread="1.2049"/>
                    <measurement group_id="O2" value="2.1" spread="3.22"/>
                    <measurement group_id="O3" value="1.9" spread="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>180 Minutes (n=31, 29, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.260" spread="1.2218"/>
                    <measurement group_id="O2" value="3.8" spread="12.77"/>
                    <measurement group_id="O3" value="2.5" spread="3.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>﻿Health-related Quality of Live (HRQoL) Short Form- 36 (SF-36) Score(s)</title>
        <description>Absolute HRQoL SF-36 Scores at end of the Months 3, 6 and 12 from s.c. baseline. SF-36, a 36-Item Short Form Health Survey (SF-36) is a set of generic, coherent, and easily administered quality-of-life measures. These measures rely upon patient self-reporting. Items are scored so that a high score defines a more favorable health state. In addition, each item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively.</description>
        <time_frame>M3, M6, M12</time_frame>
        <population>The sc full analysis set (sc FAS) consisted of all patients who received at least one dose of pasireotide sc during core sc phase. The LAR full analysis set (LAR FAS) consisted of all patients who received at least one dose of pasireotide LAR during core LAR phase.</population>
        <group_list>
          <group group_id="O1">
            <title>SOM230 - 3 Months (sc)</title>
            <description>Subjects with dumping syndrome treated with pasireotide sc</description>
          </group>
          <group group_id="O2">
            <title>SOM230 - 6 Months (LAR)</title>
            <description>Subjects with dumping syndrome treated with pasireotide sc (3M) followed by pasireotide LAR (3M) for a total of 6 months</description>
          </group>
          <group group_id="O3">
            <title>SOM230 - 12 Months (Ext)</title>
            <description>Subjects with dumping syndrome treated with pasireotide LAR (6 months in Core &amp; 6 months in Ext. phase)</description>
          </group>
        </group_list>
        <measure>
          <title>﻿Health-related Quality of Live (HRQoL) Short Form- 36 (SF-36) Score(s)</title>
          <description>Absolute HRQoL SF-36 Scores at end of the Months 3, 6 and 12 from s.c. baseline. SF-36, a 36-Item Short Form Health Survey (SF-36) is a set of generic, coherent, and easily administered quality-of-life measures. These measures rely upon patient self-reporting. Items are scored so that a high score defines a more favorable health state. In addition, each item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively.</description>
          <population>The sc full analysis set (sc FAS) consisted of all patients who received at least one dose of pasireotide sc during core sc phase. The LAR full analysis set (LAR FAS) consisted of all patients who received at least one dose of pasireotide LAR during core LAR phase.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical Component Summary (n=35, 29, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.801" spread="8.3378"/>
                    <measurement group_id="O2" value="45.306" spread="9.5622"/>
                    <measurement group_id="O3" value="46.505" spread="8.5105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Summary (n=35, 29, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.093" spread="12.2144"/>
                    <measurement group_id="O2" value="44.838" spread="11.6573"/>
                    <measurement group_id="O3" value="47.021" spread="11.5053"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>﻿Dumping Severity Score (DSS) at the End of Months 3, 6 and 8</title>
        <description>Absolute Dumping Severity Score (DSS) scores at end of M3, M6 &amp; M8. At study start patients were assessed using DSS (older version of DSQ); however after the implementation of protocol amendment 2, all patients were expected to use DSQ. No results available for M12 as last patient that answered the DSS was at M8. DSS = disease-specific patient (Pt.) reported outcome (PRO) questionnaire uses a 4-point Likert scale (0, absent; 1, mild; 2, relevant; 3, severe; 4) to ask Pt. to evaluate intensity of early dumping symptoms (within 30 minutes (&lt;30 minutes) after food ingestion). The questionnaire also evaluates 65 late dumping symptoms (more than 1.5 hours (&gt;90 minutes) after food ingestion). Early &amp; late dumping score calculated by adding the scores of the respective questions. Cumulative dumping score is obtained by adding early &amp; late scores. DSS Range (min (absent) – max (severe)): Early dumping: 0-24; Late Dumping: 0-18; Cumulative: 0-42. Lower scores represent a better outcome.</description>
        <time_frame>M3, M6, M8</time_frame>
        <population>The sc full analysis set (sc FAS) consisted of all patients who received at least one dose of pasireotide sc during core sc phase. The LAR full analysis set (LAR FAS) consisted of all patients who received at least one dose of pasireotide LAR during core LAR phase.</population>
        <group_list>
          <group group_id="O1">
            <title>SOM230 - 3 Months (sc)</title>
            <description>Subjects with dumping syndrome treated with pasireotide sc</description>
          </group>
          <group group_id="O2">
            <title>SOM230 - 6 Months (LAR)</title>
            <description>Subjects with dumping syndrome treated with pasireotide sc (3M) followed by pasireotide LAR (3M) for a total of 6 months</description>
          </group>
          <group group_id="O3">
            <title>SOM230 - 8 Months (Ext)</title>
            <description>Subjects with dumping syndrome treated with pasireotide LAR (6 months in Core &amp; 6 months in Ext. phase)</description>
          </group>
        </group_list>
        <measure>
          <title>﻿Dumping Severity Score (DSS) at the End of Months 3, 6 and 8</title>
          <description>Absolute Dumping Severity Score (DSS) scores at end of M3, M6 &amp; M8. At study start patients were assessed using DSS (older version of DSQ); however after the implementation of protocol amendment 2, all patients were expected to use DSQ. No results available for M12 as last patient that answered the DSS was at M8. DSS = disease-specific patient (Pt.) reported outcome (PRO) questionnaire uses a 4-point Likert scale (0, absent; 1, mild; 2, relevant; 3, severe; 4) to ask Pt. to evaluate intensity of early dumping symptoms (within 30 minutes (&lt;30 minutes) after food ingestion). The questionnaire also evaluates 65 late dumping symptoms (more than 1.5 hours (&gt;90 minutes) after food ingestion). Early &amp; late dumping score calculated by adding the scores of the respective questions. Cumulative dumping score is obtained by adding early &amp; late scores. DSS Range (min (absent) – max (severe)): Early dumping: 0-24; Late Dumping: 0-18; Cumulative: 0-42. Lower scores represent a better outcome.</description>
          <population>The sc full analysis set (sc FAS) consisted of all patients who received at least one dose of pasireotide sc during core sc phase. The LAR full analysis set (LAR FAS) consisted of all patients who received at least one dose of pasireotide LAR during core LAR phase.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Early symptoms (n=20, 9, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="6.38"/>
                    <measurement group_id="O2" value="6.8" spread="6.46"/>
                    <measurement group_id="O3" value="9.0" spread="8.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Late symptoms (n=20, 9, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="5.42"/>
                    <measurement group_id="O2" value="6.4" spread="5.27"/>
                    <measurement group_id="O3" value="6.0" spread="4.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall score (n=20, 9, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.7" spread="11.11"/>
                    <measurement group_id="O2" value="13.2" spread="10.65"/>
                    <measurement group_id="O3" value="15.0" spread="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>﻿Dumping Score Questionnaire (DSQ) at the End of Months 3, 6 and 12</title>
        <description>Absolute Dumping Score Questionnaire (DSQ) scores at end of Months 3, 6 &amp; 12 from s.c. baseline. DSQ = disease-specific PRO scale. The questionnaire uses a 5-point Likert scale (0, none; 1, mild; 2, moderate; 3, severe; 4, very severe) to ask Pt. to evaluate intensity of 10 early dumping symptoms (within 30 minutes (&lt;30 minutes) after food ingestion). The questionnaire also evaluates 5 late dumping symptoms (more than 1.5 hours (&gt;90 minutes) after food ingestion). Early &amp; late dumping score calculated by adding the scores of respective questions. A cumulative dumping score is obtained by adding early &amp; late scores. At study start patients were assessed using DSS (older version of DSQ); however after the implementation of protocol amendment 2, all patients used DSQ. DSQ Range: (min (None) – max (Very severe)): Early dumping: 0-40; Late Dumping: 0-20; Cumulative: 0-60. Lower scores represent a better outcome.</description>
        <time_frame>M3, M6, M12</time_frame>
        <population>The sc full analysis set (sc FAS) consisted of all patients who received at least one dose of pasireotide sc during core sc phase. The LAR full analysis set (LAR FAS) consisted of all patients who received at least one dose of pasireotide LAR during core LAR phase.</population>
        <group_list>
          <group group_id="O1">
            <title>SOM230 - 3 Months (sc)</title>
            <description>Subjects with dumping syndrome treated with pasireotide sc</description>
          </group>
          <group group_id="O2">
            <title>SOM230 - 6 Months (LAR)</title>
            <description>Subjects with dumping syndrome treated with pasireotide sc (3M) followed by pasireotide LAR (3M) for a total of 6 months</description>
          </group>
          <group group_id="O3">
            <title>SOM230 - 12 Months (Ext)</title>
            <description>Subjects with dumping syndrome treated with pasireotide LAR (6 months in Core &amp; 6 months in Ext. phase)</description>
          </group>
        </group_list>
        <measure>
          <title>﻿Dumping Score Questionnaire (DSQ) at the End of Months 3, 6 and 12</title>
          <description>Absolute Dumping Score Questionnaire (DSQ) scores at end of Months 3, 6 &amp; 12 from s.c. baseline. DSQ = disease-specific PRO scale. The questionnaire uses a 5-point Likert scale (0, none; 1, mild; 2, moderate; 3, severe; 4, very severe) to ask Pt. to evaluate intensity of 10 early dumping symptoms (within 30 minutes (&lt;30 minutes) after food ingestion). The questionnaire also evaluates 5 late dumping symptoms (more than 1.5 hours (&gt;90 minutes) after food ingestion). Early &amp; late dumping score calculated by adding the scores of respective questions. A cumulative dumping score is obtained by adding early &amp; late scores. At study start patients were assessed using DSS (older version of DSQ); however after the implementation of protocol amendment 2, all patients used DSQ. DSQ Range: (min (None) – max (Very severe)): Early dumping: 0-40; Late Dumping: 0-20; Cumulative: 0-60. Lower scores represent a better outcome.</description>
          <population>The sc full analysis set (sc FAS) consisted of all patients who received at least one dose of pasireotide sc during core sc phase. The LAR full analysis set (LAR FAS) consisted of all patients who received at least one dose of pasireotide LAR during core LAR phase.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Early symptoms (n=15, 20, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6" spread="10.27"/>
                    <measurement group_id="O2" value="9.2" spread="10.05"/>
                    <measurement group_id="O3" value="10.7" spread="10.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Late symptoms (n=15, 20, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="5.37"/>
                    <measurement group_id="O2" value="5.6" spread="6.57"/>
                    <measurement group_id="O3" value="5.7" spread="5.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall score (n=15, 20, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" spread="15.26"/>
                    <measurement group_id="O2" value="14.8" spread="14.65"/>
                    <measurement group_id="O3" value="16.3" spread="16.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Assessment at the End of Months 3, 6 and 12</title>
        <description>Treatment with pasireotide LAR (both early and late dumping scores), was assessed by patient global assessment. Patient Global Assessment served as an additional approach to symptom based measurement by DSQ. It incorporated a patient global assessment question:
“Considering all the ways that your disease affects you, rate how you are feeling during the last 7 days compared with your situation before starting the study” .Patients Global Assessment was measured utilizing a 7 point scale (from 1=a lot worse to 7= a lot better).</description>
        <time_frame>M3, M6, M12</time_frame>
        <population>The sc full analysis set (sc FAS) consisted of all patients who received at least one dose of pasireotide sc during core sc phase. The LAR full analysis set (LAR FAS) consisted of all patients who received at least one dose of pasireotide LAR during core LAR phase.</population>
        <group_list>
          <group group_id="O1">
            <title>SOM230 - 3 Months (sc)</title>
            <description>Subjects with dumping syndrome treated with pasireotide sc</description>
          </group>
          <group group_id="O2">
            <title>SOM230 - 6 Months (LAR)</title>
            <description>Subjects with dumping syndrome treated with pasireotide sc (3M) followed by pasireotide LAR (3M) for a total of 6 months</description>
          </group>
          <group group_id="O3">
            <title>SOM230 - 12 Months (Ext)</title>
            <description>Subjects with dumping syndrome treated with pasireotide LAR (6 months in Core &amp; 6 months in Ext. phase)</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Assessment at the End of Months 3, 6 and 12</title>
          <description>Treatment with pasireotide LAR (both early and late dumping scores), was assessed by patient global assessment. Patient Global Assessment served as an additional approach to symptom based measurement by DSQ. It incorporated a patient global assessment question:
“Considering all the ways that your disease affects you, rate how you are feeling during the last 7 days compared with your situation before starting the study” .Patients Global Assessment was measured utilizing a 7 point scale (from 1=a lot worse to 7= a lot better).</description>
          <population>The sc full analysis set (sc FAS) consisted of all patients who received at least one dose of pasireotide sc during core sc phase. The LAR full analysis set (LAR FAS) consisted of all patients who received at least one dose of pasireotide LAR during core LAR phase.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="1.19"/>
                    <measurement group_id="O2" value="5.1" spread="1.27"/>
                    <measurement group_id="O3" value="5.9" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Pharmacokinetic (PK) Parameter of Pasireotide: Cmax, ss (Steady State) and Ctrough, ss, After s.c. Injection</title>
        <description>A pre-dose PK blood sample was collected before the morning pasireotide s.c. dose of 50 μg, 100 ug, 150 ug and 200 ug. OGTT was performed right after the morning s.c. dose (Time point zero); additional PK blood samples were collected at the same time points as the OGTT evaluation at 30, 60, 90, 120, 150 and 180 minutes. 'n' = number of subjects with non-missing values</description>
        <time_frame>M1 to M3</time_frame>
        <population>The sc PK analysis set consisted of all patients who received at least one of the scheduled full daily sc dose (3 injections) and had evaluable PK data (concentration) in the sc dose escalation phase of the study (Visit 2 through Visit 8).</population>
        <group_list>
          <group group_id="O1">
            <title>SOM sc 50 ug t.i.d.</title>
            <description>Subjects with dumping syndrome treated with pasireotide sc 50 ug t.i.d. for 3 months</description>
          </group>
          <group group_id="O2">
            <title>SOM sc 100 ug t.i.d.</title>
            <description>Subjects with dumping syndrome treated with pasireotide sc 100 ug t.i.d. for 3 months</description>
          </group>
          <group group_id="O3">
            <title>SOM sc 150 ug t.i.d.</title>
            <description>Subjects with dumping syndrome treated with pasireotide sc 150 ug t.i.d. for 3 months</description>
          </group>
          <group group_id="O4">
            <title>SOM sc 200 ug t.i.d.</title>
            <description>Subjects with dumping syndrome treated with pasireotide sc 200 ug t.i.d.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pharmacokinetic (PK) Parameter of Pasireotide: Cmax, ss (Steady State) and Ctrough, ss, After s.c. Injection</title>
          <description>A pre-dose PK blood sample was collected before the morning pasireotide s.c. dose of 50 μg, 100 ug, 150 ug and 200 ug. OGTT was performed right after the morning s.c. dose (Time point zero); additional PK blood samples were collected at the same time points as the OGTT evaluation at 30, 60, 90, 120, 150 and 180 minutes. 'n' = number of subjects with non-missing values</description>
          <population>The sc PK analysis set consisted of all patients who received at least one of the scheduled full daily sc dose (3 injections) and had evaluable PK data (concentration) in the sc dose escalation phase of the study (Visit 2 through Visit 8).</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax, ss (n=35, 28, 18, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.49" spread="0.613"/>
                    <measurement group_id="O2" value="3.31" spread="1.78"/>
                    <measurement group_id="O3" value="4.56" spread="2.22"/>
                    <measurement group_id="O4" value="5.62" spread="3.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ctrough, ss (n=37, 30, 22, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.574" spread="0.436"/>
                    <measurement group_id="O2" value="1.11" spread="0.909"/>
                    <measurement group_id="O3" value="1.5" spread="0.798"/>
                    <measurement group_id="O4" value="2.03" spread="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Pharmacokinetic (PK) Parameter of Pasireotide: AUC0-3h, ss, After s.c. Injection</title>
        <description>A pre-dose PK blood sample was collected before the morning pasireotide s.c. dose of 50 μg, 100 ug, 150 ug and 200 ug. OGTT was performed right after the morning s.c. dose (Time point zero); additional PK blood samples were collected at the same time points as the OGTT evaluation at 30, 60, 90, 120, 150 and 180 minutes.</description>
        <time_frame>M1 to M3</time_frame>
        <population>The sc PK analysis set consisted of all patients who received at least one of the scheduled full daily sc dose (3 injections) and had evaluable PK data (concentration) in the sc dose escalation phase of the study (Visit 2 through Visit 8).</population>
        <group_list>
          <group group_id="O1">
            <title>SOM sc 50 ug t.i.d.</title>
            <description>Subjects with dumping syndrome treated with pasireotide sc 50 ug t.i.d. for 3 months</description>
          </group>
          <group group_id="O2">
            <title>SOM sc 100 ug t.i.d.</title>
            <description>Subjects with dumping syndrome treated with pasireotide sc 100 ug t.i.d. for 3 months</description>
          </group>
          <group group_id="O3">
            <title>SOM sc 150 ug t.i.d.</title>
            <description>Subjects with dumping syndrome treated with pasireotide sc 150 ug t.i.d. for 3 months</description>
          </group>
          <group group_id="O4">
            <title>SOM sc 200 ug t.i.d.</title>
            <description>Subjects with dumping syndrome treated with pasireotide sc 200 ug t.i.d.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pharmacokinetic (PK) Parameter of Pasireotide: AUC0-3h, ss, After s.c. Injection</title>
          <description>A pre-dose PK blood sample was collected before the morning pasireotide s.c. dose of 50 μg, 100 ug, 150 ug and 200 ug. OGTT was performed right after the morning s.c. dose (Time point zero); additional PK blood samples were collected at the same time points as the OGTT evaluation at 30, 60, 90, 120, 150 and 180 minutes.</description>
          <population>The sc PK analysis set consisted of all patients who received at least one of the scheduled full daily sc dose (3 injections) and had evaluable PK data (concentration) in the sc dose escalation phase of the study (Visit 2 through Visit 8).</population>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.04" spread="1.13"/>
                    <measurement group_id="O2" value="6.53" spread="3.45"/>
                    <measurement group_id="O3" value="8.84" spread="3.89"/>
                    <measurement group_id="O4" value="11.5" spread="6.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Pharmacokinetic (PK) Parameter of Pasireotide: Tmax, ss, After s.c. Injection</title>
        <description>A pre-dose PK blood sample was collected before the morning pasireotide s.c. dose of 50 μg, 100 ug, 150 ug and 200 ug. OGTT was performed right after the morning s.c. dose (Time point zero); additional PK blood samples were collected at the same time points as the OGTT evaluation at 30, 60, 90, 120, 150 and 180 minutes.</description>
        <time_frame>M1 to M3</time_frame>
        <population>The sc PK analysis set consisted of all patients who received at least one of the scheduled full daily sc dose (3 injections) and had evaluable PK data (concentration) in the sc dose escalation phase of the study (Visit 2 through Visit 8).</population>
        <group_list>
          <group group_id="O1">
            <title>SOM sc 50 ug t.i.d.</title>
            <description>Subjects with dumping syndrome treated with pasireotide sc 50 ug t.i.d. for 3 months</description>
          </group>
          <group group_id="O2">
            <title>SOM sc 100 ug t.i.d.</title>
            <description>Subjects with dumping syndrome treated with pasireotide sc 100 ug t.i.d. for 3 months</description>
          </group>
          <group group_id="O3">
            <title>SOM sc 150 ug t.i.d.</title>
            <description>Subjects with dumping syndrome treated with pasireotide sc 150 ug t.i.d. for 3 months</description>
          </group>
          <group group_id="O4">
            <title>SOM sc 200 ug t.i.d.</title>
            <description>Subjects with dumping syndrome treated with pasireotide sc 200 ug t.i.d.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pharmacokinetic (PK) Parameter of Pasireotide: Tmax, ss, After s.c. Injection</title>
          <description>A pre-dose PK blood sample was collected before the morning pasireotide s.c. dose of 50 μg, 100 ug, 150 ug and 200 ug. OGTT was performed right after the morning s.c. dose (Time point zero); additional PK blood samples were collected at the same time points as the OGTT evaluation at 30, 60, 90, 120, 150 and 180 minutes.</description>
          <population>The sc PK analysis set consisted of all patients who received at least one of the scheduled full daily sc dose (3 injections) and had evaluable PK data (concentration) in the sc dose escalation phase of the study (Visit 2 through Visit 8).</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.583" lower_limit="0" upper_limit="1.58"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="0.583" lower_limit="0.5" upper_limit="2.6"/>
                    <measurement group_id="O4" value="0.633" lower_limit="0.5" upper_limit="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma PK Parameter of AUC0-3h, d21, End _inj and AUC0-3h, d28, 3rd_inj Associated With LAR (LAR Core Phase)</title>
        <time_frame>M4 to M6</time_frame>
        <population>The LAR PK analysis set consisted of all patients who received at least one of the scheduled full monthly im LAR injections and had evaluable PK data (concentration) in the LAR phase of the study (Visit 9 through end of LAR phase visit).</population>
        <group_list>
          <group group_id="O1">
            <title>SOM LAR 10mg</title>
            <description>Subjects with dumping syndrome treated with pasireotide LAR 10mg</description>
          </group>
          <group group_id="O2">
            <title>SOM LAR 20mg</title>
            <description>Subjects with dumping syndrome treated with pasireotide LAR 20mg</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma PK Parameter of AUC0-3h, d21, End _inj and AUC0-3h, d28, 3rd_inj Associated With LAR (LAR Core Phase)</title>
          <population>The LAR PK analysis set consisted of all patients who received at least one of the scheduled full monthly im LAR injections and had evaluable PK data (concentration) in the LAR phase of the study (Visit 9 through end of LAR phase visit).</population>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC0-3h,d21, 2nd injection (n = 12, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.92" spread="4.12"/>
                    <measurement group_id="O2" value="14.9" spread="6.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC0-3h,d28, 3rd_injection (n = 9, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.97" spread="2.41"/>
                    <measurement group_id="O2" value="9.3" spread="4.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of LAR PK Parameters by Dose</title>
        <description>Summary of plasma PK parameter Cmax, p2 , 2nd injection and Ctrough, d28 associated with LAR injection (LAR Core phase)</description>
        <time_frame>M4 to M6</time_frame>
        <population>The LAR PK analysis set consisted of all patients who received at least one of the scheduled full monthly im LAR injections and had evaluable PK data (concentration) in the LAR phase of the study (Visit 9 through end of LAR phase visit).</population>
        <group_list>
          <group group_id="O1">
            <title>SOM LAR 10mg</title>
            <description>Subjects with dumping syndrome treated with pasireotide LAR 10mg</description>
          </group>
          <group group_id="O2">
            <title>SOM LAR 20mg</title>
            <description>Subjects with dumping syndrome treated with pasireotide LAR 20mg</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of LAR PK Parameters by Dose</title>
          <description>Summary of plasma PK parameter Cmax, p2 , 2nd injection and Ctrough, d28 associated with LAR injection (LAR Core phase)</description>
          <population>The LAR PK analysis set consisted of all patients who received at least one of the scheduled full monthly im LAR injections and had evaluable PK data (concentration) in the LAR phase of the study (Visit 9 through end of LAR phase visit).</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax, p2, 2nd_inj (n = 10, 13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="1.55"/>
                    <measurement group_id="O2" value="6.2" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ctrough (n= 14, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.29" spread="1.05"/>
                    <measurement group_id="O2" value="3.33" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pasireotide Concentrations in LAR Phase</title>
        <description>Summary of pasireotide concentrations following monthly i.m. injections of pasireotide LAR by incident dose (LAR Pharmacokinetic set)</description>
        <time_frame>M7 to M12</time_frame>
        <population>The LAR PK analysis set consisted of all patients who received at least one of the scheduled full monthly im LAR injections and had evaluable PK data (concentration) in the LAR phase of the study (Visit 9 through end of LAR phase visit).</population>
        <group_list>
          <group group_id="O1">
            <title>SOM LAR 10mg</title>
            <description>Subjects with dumping syndrome treated with pasireotide LAR 10mg</description>
          </group>
          <group group_id="O2">
            <title>SOM LAR 20mg</title>
            <description>Subjects with dumping syndrome treated with pasireotide LAR 20mg</description>
          </group>
          <group group_id="O3">
            <title>SOM LAR 30mg</title>
            <description>Subjects with dumping syndrome treated with pasireotide LAR 30mg</description>
          </group>
          <group group_id="O4">
            <title>SOM LAR 40mg</title>
            <description>Subjects with dumping syndrome treated with pasireotide LAR 40mg</description>
          </group>
          <group group_id="O5">
            <title>SOM LAR 60mg</title>
            <description>Subjects with dumping syndrome treated with pasireotide LAR 60mg</description>
          </group>
        </group_list>
        <measure>
          <title>Pasireotide Concentrations in LAR Phase</title>
          <description>Summary of pasireotide concentrations following monthly i.m. injections of pasireotide LAR by incident dose (LAR Pharmacokinetic set)</description>
          <population>The LAR PK analysis set consisted of all patients who received at least one of the scheduled full monthly im LAR injections and had evaluable PK data (concentration) in the LAR phase of the study (Visit 9 through end of LAR phase visit).</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>M7 - 0hr (pre-dose) (n = 4, 11, 11, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.25" spread="1.56"/>
                    <measurement group_id="O2" value="4.3" spread="2.19"/>
                    <measurement group_id="O3" value="7.76" spread="4.31"/>
                    <measurement group_id="O4" value="NA">N/A = No participants took this dose hence no data</measurement>
                    <measurement group_id="O5" value="NA">N/A =No participants took this dose hence no data</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M8 - 0hr (pre-dose) (n = 5, 7, 11, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.91" spread="2.42"/>
                    <measurement group_id="O2" value="3.77" spread="1.57"/>
                    <measurement group_id="O3" value="6.5" spread="2.91"/>
                    <measurement group_id="O4" value="NA">N/A = No participants took this dose hence no data</measurement>
                    <measurement group_id="O5" value="NA">N/A = No participants took this dose hence no data</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M9 - 0hr (pre-dose) (n = 5, 6, 9, 6, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.97" spread="1.68"/>
                    <measurement group_id="O2" value="4.01" spread="2.27"/>
                    <measurement group_id="O3" value="6.38" spread="3.15"/>
                    <measurement group_id="O4" value="7.53" spread="4.45"/>
                    <measurement group_id="O5" value="NA">N/A = No participants took this dose hence no data</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10 - 0hr (pre-dose) (n = 5, 6, 8, 5, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.53" spread="1.75"/>
                    <measurement group_id="O2" value="5.48" spread="3.62"/>
                    <measurement group_id="O3" value="8.38" spread="2.81"/>
                    <measurement group_id="O4" value="11.8" spread="8.26"/>
                    <measurement group_id="O5" value="NA">N/A = No participants took this dose hence no data</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M11 - 0hr (pre-dose) (n = 5, 4, 8, 4, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.45" spread="1.98"/>
                    <measurement group_id="O2" value="3.48" spread="0.772"/>
                    <measurement group_id="O3" value="7.99" spread="3.54"/>
                    <measurement group_id="O4" value="6.53" spread="1.83"/>
                    <measurement group_id="O5" value="17.9" spread="7.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M12 - 0hr (pre-dose) (n = 5, 3, 8, 4, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.27" spread="2.02"/>
                    <measurement group_id="O2" value="4.63" spread="1.04"/>
                    <measurement group_id="O3" value="10.3" spread="6.05"/>
                    <measurement group_id="O4" value="6.55" spread="2.05"/>
                    <measurement group_id="O5" value="18.1" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LAR PK Parameter: Ctrough - at Steady State (ss) by Dose</title>
        <description>In the LAR treatment phase, monthly injections of pasireotide LAR 10, 20, 30 and 40 mg were given to participants and trough concentration at steady state (Ctrough,ss) were obtained but due to only 1 participant in the 40mg arm, standard deviation could not be calculated.</description>
        <time_frame>M4 to M12</time_frame>
        <population>The LAR PK analysis set consisted of all patients who received at least one of the scheduled full monthly im LAR injections and had evaluable PK data (concentration) in the LAR phase of the study (Visit 9 through end of LAR phase visit).</population>
        <group_list>
          <group group_id="O1">
            <title>SOM LAR 10mg</title>
            <description>Subjects with dumping syndrome treated with pasireotide LAR 10mg</description>
          </group>
          <group group_id="O2">
            <title>SOM LAR 20mg</title>
            <description>Subjects with dumping syndrome treated with pasireotide LAR 20mg</description>
          </group>
          <group group_id="O3">
            <title>SOM LAR 30mg</title>
            <description>Subjects with dumping syndrome treated with pasireotide LAR 30mg</description>
          </group>
          <group group_id="O4">
            <title>SOM LAR 40mg</title>
            <description>Subjects with dumping syndrome treated with pasireotide LAR 40mg</description>
          </group>
        </group_list>
        <measure>
          <title>LAR PK Parameter: Ctrough - at Steady State (ss) by Dose</title>
          <description>In the LAR treatment phase, monthly injections of pasireotide LAR 10, 20, 30 and 40 mg were given to participants and trough concentration at steady state (Ctrough,ss) were obtained but due to only 1 participant in the 40mg arm, standard deviation could not be calculated.</description>
          <population>The LAR PK analysis set consisted of all patients who received at least one of the scheduled full monthly im LAR injections and had evaluable PK data (concentration) in the LAR phase of the study (Visit 9 through end of LAR phase visit).</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.34" spread="1.52"/>
                    <measurement group_id="O2" value="3.76" spread="1.48"/>
                    <measurement group_id="O3" value="8.19" spread="3.22"/>
                    <measurement group_id="O4" value="4.63">N/A - due to only one participant at LAR 40 mg, Ctrough,ss for this arm was not enough to a standard deviation</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>s.c. Phase</title>
          <description>s.c. phase was made up of subjects with dumping syndrome who entered the study and were treated with pasireotide s.c.</description>
        </group>
        <group group_id="E2">
          <title>LAR Phase</title>
          <description>LAR phase was made up of subjects with dumping syndrome who completed the s.c. phase, entered the LAR phase and were treated with pasireotide LAR</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Subdiaphragmatic abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Visual field defect</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Steatorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Post-traumatic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Iron deficiency</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>All safety parameters were analyzed by study phase (sc/LAR)</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>trialandresults.registries@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

